A case of planned pregnancy with an interruption in infliximab administration in a 27-year-old female patient with rheumatoidfactor- positive polyarthritis juvenile idiopathic arthritis which improved after restarting infliximab and methotrexate
Yasuhito Nerome1 , Hiroyuki Imanaka1 , Yukiko Nonaka1 , Yumiko Tsuru1 , Nobuaki Maeno1 , Tomoko Takezaki1 , Hirosumi Mori1 , Harumi Akaike1 , Tomohiro Kubota1 , Yoshifumi Kawano1 , Syuji Takei1
13 August 2007
24 October 2007
15 February 2008
PDF (member's only)
We report a 27-year-old case of juvenile idiopathic arthritis (JIA) having been stopped infliximab during pregnancy. She was safely treated by infliximab therapy with premedications for preventing infusin reactions after her delivery, and then improved in the same manner as when she had been treated with infliximab therapy before pregnancy. As a result, it remains unclear whether or not we can use infliximab to control disease activities during pregnancy. In addition, it is also important to clarify whether or not premedications should be used when resuming infliximab treatment in such patients after pregnancy. These problems still remain controversial. More definitive data are needed in order to allow rheumatologists to better select the optimal TNF-alpha inhibitor therapy when treating pregnant JIA patients.
Pregnancy - Infliximab - Juvenile idiopathic arthritis